]>
IRCT20200515047456N1 IRCT 2020-06-28 Tabriz University of Medical Sciences The role of anticoagulant and thrombolitic in treatment of COVID patients TACOVID Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient 2020-06-17 anticipated 15 Complete https://irct.ir/trial/48929 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization by block method and Randlist software according to Seed schedule with 420059136 number, Blinding description: Only participants in this study were blinded, given that the patients are unconscious and under mechanical ventilation. 3 COVID 19. Intervention 1: Control group: Without placebo. Intervention 2: Intervention group: first intervention group, anticoagulant. ، the patients will be started on unfractional heparin. Blood sample will tale to keep PTT more than 50. Intervention 3: Intervention group: second intervention group, thrombolytic ( tPA). The will be started 25 mg over 2 hours and 25 mg for next 22 hours. Yes - There is a plan to make this available What will be shared: Demographic information When: Six month after publication To whom: Researchers who work in university Conditions: Only for information Where to obtain: Via e.mail How to obtain: Send a request via e.mail Comments:
public Farid Rashidi
Daneshgah
تبریز Iran (Islamic Republic of) 5166614756 +98 41 3336 4901 fr2652@yahoo.com Tabriz University of Medical Sciences scientific Farid Rashidi
Daneshgah
Tabriz Iran (Islamic Republic of) 5166614756 +98 41 3336 0901 fr2652@yahoo.com Tabriz University of Medical Sciences Iran (Islamic Republic of) COVID patients with P/F ratio less than 100 D.dimer more than 3000 without response to other medications 15 years 70 years Both Active bleeding Platelet less than 30000 Without any contraindication for thrombolytic therapy U07.1 COVID-19, virus identified Treatment - Drugs Treatment - Drugs Treatment - Drugs Control group: Without placebo Intervention group: first intervention group, anticoagulant. ، the patients will be started on unfractional heparin. Blood sample will tale to keep PTT more than 50 Intervention group: second intervention group, thrombolytic ( tPA). The will be started 25 mg over 2 hours and 25 mg for next 22 hours Improve of oxygenasion. Timepoint: From first to 6th days of study. Method of measurement: Arterial blood gas. Improve SOFA score. Timepoint: From first to 6th days of study. Method of measurement: Questionnaire. Improve compliance. Timepoint: From first to 6th days of study. Method of measurement: Ventilator parameter. Decrease d.Dimer level. Timepoint: From first to 6th days of study. Method of measurement: Blood sample. Tabriz University of Medical Sciences Approved 2020-05-18 Ethics committee of Tabriz University of Medical Sciences Farid Rashidi, MD, Tuberculosis and Lung diseases research center, Imam Reza Hospital, Daneshgah St, Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)